CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 193-209

  Conti Fine, Bianca M ^a   Milani, Monica ^b   Wang, Wei ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Acetylcholine receptor; Acquired myasthenia gravis; Complement; Cytokines; Experimental autoimmune myasthenia gravis

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; COMPLEMENT; CYTOKINE; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; STAT PROTEIN;

CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL GROWTH; CELL SECRETION; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE COURSE; EXPERIMENTAL MODEL; IMMUNE RESPONSE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATHOGENESIS; SYMPTOM; TH1 CELL; TH2 CELL;

EID: 45549110006     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.042     Document Type: Conference Paper

References (111)

1. Conti-Fine, B.M., M. Protti, M. Bellone & J.F. Howard, Jr. 1997. Myasthenia Gravis: The Immunobiology of an Autoimmune Disease. R.G. Landes Company. Austin, TX.
2. Conti-Fine, B.M., M. Milani & H.J. Kaminski. 2006. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116 : 2843 2854.
3. Vincent, A. & D.B. Drachman. 2002. Myasthenia gravis. Adv. Neurol. 88 : 159 188.
4. Berman, P.W. & J. Patrick. 1980. Experimental myasthenia gravis. A murine system. J. Exp. Med. 151 : 204 223.
5. Lennon V.A., J.M. Lindstrom & M.E. Seybold. 1975. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141 : 1365 1375.
6. Engel, A.G., E.H. Lambert & F.M. Howard. 1977. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52 : 267 280.
7. Sahashi, K., A.G. Engel, E.H. Lambert & F.M. Howard Jr. 1980. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39 : 160 172.
8. Fazekas, A., S. Komoly, B. Bozsik & A. Szobor. 1986. Myasthenia gravis: demonstration of membrane attack complex in muscle end-plates. Clin. Neuropathol. 5 : 78 83.
9. Lennon, V.A., M.E. Seybold, J.M. Lindstrom, et al. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147 : 973 983.
10. Biesecker, G. & C.M. Gomez. 1989. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142 : 2654 2659.
11. Piddlesden, S.J., S. Jiang, J.L. Levin, et al. 1996. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71 : 173 177.
12. Christadoss, P. 1988. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140 : 2589 2592.
13. Karachunski, P.I., N.S. Ostlie, C. Monfardini & B.M. Conti-Fine. 2000. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164 : 5236 5244.
14. Medof, M.E., E.I. Walter, J.L. Rutgers, et al. 1987. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165 : 848 864.
15. McNearney, T., L. Ballard, T. Seya & J.P. Atkinson. 1989. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J. Clin. Invest. 84 : 538 545.
16. Meri, S., H. Waldmann & P.J. Lachmann. 1991. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab. Invest. 65 : 532 537.
17. Lin, F., Y. Fukuoka, A. Spicer, et al. 2001. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 104 : 215 225.
18. Spicer, A.P., M.F. Seldin & S.J. Gendler. 1995. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J. Immunol. 155 : 3079 3091.
19. Lin, F., H.J. Kaminski, B.M. Conti-Fine, et al. 2002. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J. Clin. Invest. 110 : 1269 1274.
20. Eng, H., A.K. Lefvert, H. Mellstedt & A. Osterborg. 1987. Human monoclonal immunoglobulins that bind the human acetylcholine receptor. Eur. J. Immunol. 17 : 1867 1869.
21. Hohlfeld, R., K.V. Toyka, K. Heininger, et al. 1984. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 310 : 244 246.
22. Morgutti, M., B.M. Conti-Tronconi, A. Sghirlanzoni & F. Clementi. 1979. Cellular immune response to acetylcholine receptor in myasthenia gravis: II. Thymectomy and corticosteroids. Neurology 29 : 734 738.
23. Ahlberg, R., Q. Yi, R. Pirskanen, G. Matell, et al. 1994. Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 44 : 1732 1737.
24. Nath, A., R.H. Kerman, I.S. Novak & J.S. Wolinsky. 1990. Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report. Neurology 40 : 581 583.
25. Wang, Z.Y., P.I. Karachunski, J.F. Howard Jr. & B.M. Conti-Fine. 1999. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes: role of CD4+ and CD8+ cells. Neurology 52 : 484 497.
26. Kaul, R., M. Shenoy, E. Goluszko & P. Christadoss. 1994. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152 : 3152 3157.
27. Moiola, L., P. Karachunski, M.P. Protti, et al. 1994. Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects. J. Clin. Invest. 93 : 1020 1028.
28. Wang, Z.Y., D.K. Okita, J. Howard Jr. & B.M. Conti-Fine. 1998. T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis. Neurology 50 : 1045 1054.
29. Wang, Z.Y., B. Diethelm-Okita, D.K. Okita, et al. 2000. T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis. J. Neuroimmunol. 108 : 29 39.
30. Protti, M.P., A.A. Manfredi, C. Straub, et al. 1990. Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc. Natl. Acad. Sci. USA 87 : 7792 7796.
31. Kolls, J.K. & A. Linden. 2004. Interleukin-17 family members and inflammation. Immunity 21 : 467 476.
32. Komiyama, Y., S. Nakae, T. Matsuki, et al. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177 : 566 573.
33. Abbas, A.K., K.M. Murphy & A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383 : 787 793.
34. Romagnani, S. 1999. Th1/Th2 cells. Inflammatory Bowel Dis. 5 : 285 294.
35. Veldhoen, M., R.J. Hocking, C.J. Atkins, et al. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 : 179 189.
36. Weiner, H.L. 2001. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. 182 : 207 214.
37. Battaglia, M., B.R. Blazar & M.G. Roncarolo. 2002. The puzzling world of murine T regulatory cells. Microbes Infect. 4 : 559 566.
38. Yi, Q., R. Ahlberg, R. Pirskanen & A.K. Lefvert. 1994. Acetylcholine receptor-reactive T cells in myasthenia gravis: evidence for the involvement of different subpopulations of T helper cells. J. Neuroimmunol. 50 : 177 186.
39. Ostlie, N.S., P.I. Karachunski, W. Wang, et al. 2001. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. J. Immunol. 166 : 4853 4862.
40. Poussin, M.A., E. Goluszko, T.K. Hughes, et al. 2000. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. 111 : 152 160.
41. Deng, C., E. Goluszko, E. Tuzun, et al. 2002. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169 : 1077 1083.
42. Moiola, L., F. Galbiati, G. Martino, et al. 1998. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28 : 2487 2497.
43. Goluszko, E., C. Deng, M.A. Poussin & P. Christadoss. 2002. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J. Neuroimmunol. 122 : 85 93.
44. Wang, H.B., H. Li, F.D. Shi, et al. 2000. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. Int. Immunol. 12 : 1381 1388.
45. Takeda, K. & S. Akira. 2000. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 11 : 199 207.
46. O'Shea, J.J. 1997. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7 : 1 11.
47. Ihle, J.N. 2001. The Stat family in cytokine signaling. Curr. Opin. Cell Biol. 13 : 211 217.
48. Akira, S. 1999. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17 : 138 146.
49. Berman, P.W. & J. Patrick. 1980. Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis. J. Exp. Med. 152 : 507 520.
50. Christadoss, P. 1989. Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9 : 247 278.
51. Bellone, M., N. Ostlie, S. Lei & B.M. Conti-Tronconi. 1991. Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors. Eur. J. Immunol. 21 : 2303 2310.
52. Wang, W., N.S. Ostlie, B.M. Conti-Fine & M. Milani. 2004. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells. J. Immunol. 172 : 97 103.
53. Bell, J., L. Rassenti, S. Smoot, et al. 1986. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet 1 : 1058 1060.
54. Yang, H., E. Goluszko, C. David, et al. 2002. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J. Clin. Invest. 109 : 1111 1120.
55. Limburg, P.C., T.H. The, E. Hummel-Tappel & H.J. Oosterhuis. 1983. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J. Neurol. Sci. 58 : 357 370.
56. Balasa, B., C. Deng, J. Lee, et al. 1997. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186 : 385 391.
57. Hohlfeld, R. & A.G. Engel. 1990. Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am. J. Pathol. 136 : 503 508.
58. Link, J. 1994. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. Acta Neurol. Scand. Suppl. 158 : 1 58.
59. Wang, H.B., F.D. Shi, H. Li, et al. 2000. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin. Immunol. 95 : 156 162.
60. Feferman, T., P.K. Maiti, S. Berrih-Aknin, et al. 2005. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J. Immunol. 174 : 5324 5331.
61. Delpy, L., V. Douin-Echinard, L. Garidou, et al. 2005. Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses. J. Immunol. 175 : 5050 5057.
62. Zhang, G.X., B.G. Xiao, X.F. Bai, et al. 1999. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162 : 3775 3781.
63. Van Der Veen, R.C., J.A. Kapp & J.L. Trotter. 1993. Fine-specificity differences in the recognition of an encephalitogenic peptide by T helper 1 and 2 cells. J. Neuroimmunol. 48 : 221 226.
64. Wildbaum, G., S. Youssef, N. Grabie & N. Karin. 1998. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol. 161 : 6368 6374.
65. Panitch, H.S., R.L. Hirsch, A.S. Haley & K.P. Johnson. 1987. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1 : 893 895.
66. Ferber, I.A., S. Brocke, C. Taylor-Edwards, et al. 1996. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156 : 5 7.
67. Willenborg, D.O., S. Fordham, C.C. Bernard, et al. 1996. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157 : 3223 3227.
68. Davidson, N.J., S.A. Hudak, R.E. Lesley, et al. 1998. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J. Immunol. 161 : 3143 3149.
69. Simpson, S.J., S. Shah, M. Comiskey, et al. 1998. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J. Exp. Med. 187 : 1225 1234.
70. Egwuagu, C.E., J. Sztein, R.M. Mahdi, et al. 1999. IFN-gamma increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. J. Immunol. 162 : 510 517.
71. Jones, L.S., L.V. Rizzo, R.K. Agarwal, et al. 1997. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J. Immunol. 158 : 5997 6005.
72. Sarvetnick, N., J. Shizuru, D. Liggitt, et al. 1990. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 346 : 844 847.
73. Debray-Sachs, M., C. Carnaud, C. Boitard, et al. 1991. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J. Autoimmun. 4 : 237 248.
74. Campbell, I.L., T.W. Kay, L. Oxbrow & L.C. Harrison. 1991. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87 : 739 742.
75. Hultgren, B., X. Huang, N. Dybdal & T.A. Stewart. 1996. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 45 : 812 817.
76. Nakae, S., A. Nambu, K. Sudo & Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171 : 6173 6177.
77. Caspi, R.R., C.C. Chan, B.G. Grubbs, et al. 1994. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J. Immunol. 152 : 890 899.
78. Veldhoen, M. & B. Stockinger. 2006. TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. Trends Immunol. 27 : 358 361.
79. Wang, W., M. Milani, N. Ostlie, et al. 2007. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-{gamma} are susceptible to experimental autoimmune Myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J. Immunol. 178 : 7072 7080.
80. Aggarwal, S., N. Ghilardi, M.H. Xie, et al. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278 : 1910 1914.
81. Stockinger, B. & M. Veldhoen. 2007. Differentiation and function of Th17 T cells. Curr. Opin. Immunol. 19 : 281 286.
82. Beissert, S., A. Schwarz & T. Schwarz. 2006. Regulatory T cells. J. Invest. Dermatol. 126 : 15 24.
83. Sakaguchi, S., N. Sakaguchi, M. Asano, et al. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 : 1151 1164.
84. Nishibori, T., Y. Tanabe, L. Su & M. David. 2004. Impaired development of CD4+ CD25 +regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J. Exp. Med. 199 : 25 34.
85. Kelchtermans, H., B. De Klerck, T. Mitera, et al. 2005. Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res. Ther. 7 : R402 415.
86. Sawitzki, B., C.I. Kingsley, O. V, et al. 2005. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J. Exp. Med. 201 : 1925 1935.
87. Balandina, A., S. Lecart, P. Dartevelle, et al. 2005. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105 : 735 741.
88. Sun, Y., J. Qiao, C.Z. Lu, et al. 2004. Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy. Clin. Immunol. 112 : 284 289.
89. Godfrey, D.I. & M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114 : 1379 1388.
90. Margalit, M. & Y. Ilan. 2005. Induction of immune tolerance: a role for Natural killer T lymphocytes? Liver Int. 25 : 501 504.
91. Liu, R., A. La Cava, X.F. Bai, et al. 2005. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175 : 7898 7904.
92. Shi, F.D., H.B. Wang, H. Li, et al. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat. Immunol. 1 : 245 251.
93. Karachunski, P.I., N.S. Ostlie, D.K. Okita & B.M. Conti-Fine. 1999. Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor. J. Neuroimmunol. 95 : 73 84.
94. Ostlie, N., M. Milani, W. Wang, et al. 2003. Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J. Immunol. 170 : 604 612.
95. Karachunski, P.I., N.S. Ostlie, D.K. Okita & B.M. Conti-Fine. 1998. Nasal administration of synthetic acetylcholine receptor T epitopes affects the immune response to the acetylcholine receptor and prevents experimental myasthenia gravis. Ann. N.Y. Acad. Sci. 841 : 560 564.
96. Poussin, M.A., E. Goluszko, J.U. Franco & P. Christadoss. 2002. Role of IL-5 during primary and secondary immune response to acetylcholine receptor. J. Neuroimmunol. 125 : 51 58.
97. Constant, S.L. & K. Bottomly. 1997. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15 : 297 322.
98. Briere, F., J.M. Bridon, D. Chevet, et al. 1994. Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. J. Clin. Invest. 94 : 97 104.
99. Briere, F., C. Servet-Delprat, J.M. Bridon, et al. 1994. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J. Exp. Med. 179 : 757 762.
100. Burdin, N., C. Van Kooten, L. Galibert, et al. 1995. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J. Immunol. 154 : 2533 2544.
101. Rousset, F., S. Peyrol, E. Garcia, et al. 1995. Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. Int. Immunol. 7 : 1243 1253.
102. Malisan, F., F. Briere, J.M. Bridon, et al. 1996. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J. Exp. Med. 183 : 937 947.
103. Cerutti, A., H. Zan, A. Schaffer, et al. 1998. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line. J. Immunol. 160 : 2145 2157.
104. Hagenbaugh, A., S. Sharma, S.M. Dubinett, et al. 1997. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 185 : 2101 2110.
105. O'Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8 : 275 283.
106. Xiao, B.G. & H. Link. 1997. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin. Immunol. Immunopathol. 85 : 119 128.
107. Huang, Y.M., P. Kivisakk, V. Ozenci, et al. 1999. Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG). Clin. Exp. Immunol. 118 : 304 308.
108. Llorente, L., W. Zou, Y. Levy, et al. 1995. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 181 : 839 844.
109. Cross, J.T. & H.P. Benton. 1999. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm. Res. 48 : 255 261.
110. Bromberg, J.S. 1995. IL-10 immunosuppression in transplantation. Curr. Opin. Immunol. 7 : 639 643.
111. Akdis, C.A. & K. Blaser. 1999. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. 13 : 603 609.